Diltiazem IV Administration for SVT
For hemodynamically stable SVT, administer diltiazem as an initial IV bolus of 0.25 mg/kg (typically 20 mg) over 2 minutes, followed by a second bolus of 0.35 mg/kg 15 minutes later if needed, then start a continuous infusion at 5-15 mg/hour for ongoing rate control. 1
Initial Bolus Dosing
The standard approach begins with 0.25 mg/kg IV push over 2 minutes (typically 15-25 mg for most adults). If SVT persists after 15 minutes, give a second bolus of 0.35 mg/kg over 2 minutes. 1, 2 This achieves conversion to sinus rhythm in 86-98% of patients with AV nodal reentrant tachycardia (AVNRT) or orthodromic AV reentrant tachycardia (AVRT). 3, 1
Important caveat: Recent evidence suggests lower doses (≤0.2 mg/kg) may be equally effective while reducing hypotension risk by 60% compared to standard dosing. 4 Consider starting with 10-15 mg in elderly patients or those at risk for hypotension.
Continuous Infusion
After successful bolus conversion, start a maintenance infusion at 5-10 mg/hour, titrating up to 15 mg/hour as needed to maintain heart rate <100 bpm. 1, 5 The median effective infusion rate is typically 10-13 mg/hour. 6, 7
Critical Safety Considerations
Absolute Contraindications
- Never use diltiazem in pre-excited atrial fibrillation (visible delta waves with irregular rhythm) - this can precipitate ventricular fibrillation by enhancing accessory pathway conduction. 8, 1
- Avoid in wide-complex tachycardia of unknown etiology - could be ventricular tachycardia
- Contraindicated in hemodynamically unstable patients (use synchronized cardioversion instead)
- Avoid in systolic heart failure or severe hypotension (SBP <100 mmHg)
Downgraded Recommendation
The 2019 ESC guidelines downgraded diltiazem from Class I to Class IIa for acute narrow-QRS tachycardia management, with adenosine now preferred as first-line. 8 However, the 2015 ACC/AHA guidelines still support diltiazem as Class IIa for hemodynamically stable SVT. 1
Efficacy Expectations
- Conversion rate: 64-98% for narrow-complex SVT 1, 3
- Time to conversion: Median 2 minutes after bolus initiation 3
- AVNRT: 100% conversion rate 3
- AVRT: 81% conversion rate 3
Diltiazem is particularly effective when adenosine fails or causes intolerable side effects, and in patients who cannot tolerate beta-blockers. 1
Monitoring Requirements
- Continuous cardiac monitoring and blood pressure measurement during bolus administration
- Monitor for at least 2 hours post-conversion 9
- Have atropine (0.6-1.0 mg), calcium chloride (1 g), and cardioversion equipment immediately available 2
- Watch for hypotension (occurs in 18-42% depending on dose) 4
Transition to Oral Therapy
If maintaining rate control with IV infusion, transition to oral diltiazem CD 180-360 mg daily (typically 300 mg). Administer the first oral dose, then discontinue IV infusion 4 hours later. This maintains rate control in 77% of patients. 7
When Diltiazem May Not Be First Choice
Recent 2024 data suggests that diltiazem infusions after bolus may actually reduce rate control success compared to bolus alone in atrial fibrillation/flutter (OR 0.69). 10 Consider avoiding continuous infusion if adequate rate control is achieved with bolus dosing alone.
For patients with visible retrograde P waves or aVL notch on ECG, diltiazem achieves 95% conversion versus 72% with adenosine, making it the preferred agent in this subset. 11